NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohns disease and ulcerative colitis[1][2].
Molekulargewicht:
399.44
Reinheit:
98.11
CAS Nummer:
[2389235-01-0]
Formel:
C24H21N3O3
Target-Kategorie:
NOD-like Receptor (NLR)
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten